CD274 and neoplasm: Anti-TIGIT antibodies are being tested in combination with PD-1/PD-L1 inhibitors in mice models, with the combined blockade of TIGIT and PD-L1 signaling resulting in reduced tumor growth, increased effector T cells and subsequently enhanced immune memory effects [13].